Pfizer Venture Investments and Lundbeckfond Ventures have contributed to a fundraise that will support the orphan-drug accelerator's activities through 2021.

The capital will be used to start clinical development of a technique developed at Columbia University that could help tackle heart and metabolic diseases.

Biopharmaceutical developer Fortress Biotech has set up a new subsidiary to develop a treatment for amyloidosis licensed from Columbia University.

Bain Capital Life Sciences, Cormorant Asset Management and RA Capital co-led the Staidson-backed inflammatory disease drug developer's latest round.

Lata Hariharan takes an in-depth look at the digital health ecosystem in Israel, finding much to be cheerful about.

The insurer is offering $12,000 in seed funding as part of a new health and welfare accelerator formed in partnership with incubator H-Farm.

ImaginAb, a UCLA spinout that has now raised approximately $4m in total, will continue development of the imaging agent it is developing for T-cell tumours.

Spero Therapeutics, a bacterial infection treatment developer based on research at Harvard Medical School, has filed to raise up to $86.3m in an initial public offering.